Javascript must be enabled to continue!
Abstract 1341: Identification of significant linkage evidence for lethal prostate cancer on chromosome arm 11p15.
View through CrossRef
Abstract
We performed genome wide linkage analysis in a set of high-risk prostate cancer pedigrees, each with 3 or more sampled cases whose death certificate indicated a contribution of prostate cancer to death (lethal prostate cancer). All prostate cancer cases were present in the Utah SEER Cancer Registry (pathology confirmed); all “lethal” prostate cancer cases were also required to have a Utah death certificate indicating prostate cancer as a contributing cause of death.
A set of markers with no linkage disequilibrium was selected for linkage analysis. We took the intersection of SNP markers from five Illumina genotyping platforms used (550K, 610K, 1M,Omni_express (720k), and Omni_1M), resulting in selection of 301,646 markers. We began with the first marker on each chromosome and then skipped markers until one satisfied all criteria (min 0.1 cM distance, heterozygosity 0.35, R-squared < 0.16 -using HapMap's LD files based on CEPH). This resulted in selection of a set of 25,436 SNP LD-free genome wide markers for linkage.
We have performed genome-wide linkage analysis for 21 of the genotyped high-risk lethal prostate cancer pedigrees with the 25,436 selected SNP markers. Genome wide hetLODs showed one significant linkage peak for the recessive model on chromosome 14 (LOD = 4.20). The pedigree with the highest LOD in this region has a +2.69; we are attempting to expand sampling for other pedigrees with linkage evidence in this region.
A single pedigree with 16 prostate cancer cases, at least 4 of whom have already died from prostate cancer and were sampled, provided a LOD score = +3.56 on chromosome arm 11p15. An 11p15 haplotype inherited in common from the founder to 6 generations of descendants is shared in at least 9 of the prostate cancer cases, 3 of whom died from prostate cancer.
The 1-LOD drop defined support interval for the pedigree linked to chromosome 11 occurs at approximately 34-46 cM and contains 13 currently documented genomic features, several of which may be reasonable candidates for lethal prostate cancer including the gene PRMT3 (arginine methyltransferase 3), DAL-1, NELL1, FANCF (Fanconi anemia, complementation group F), and GAS2 (growth arrest-specific 2).
Sequencing of multiple haplotype sharing cases in the pedigree is underway.
Citation Format: Lisa A. Cannon-Albright, Craig C. Teerlink, Neeraj Agarwal. Identification of significant linkage evidence for lethal prostate cancer on chromosome arm 11p15. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1341. doi:10.1158/1538-7445.AM2013-1341
American Association for Cancer Research (AACR)
Title: Abstract 1341: Identification of significant linkage evidence for lethal prostate cancer on chromosome arm 11p15.
Description:
Abstract
We performed genome wide linkage analysis in a set of high-risk prostate cancer pedigrees, each with 3 or more sampled cases whose death certificate indicated a contribution of prostate cancer to death (lethal prostate cancer).
All prostate cancer cases were present in the Utah SEER Cancer Registry (pathology confirmed); all “lethal” prostate cancer cases were also required to have a Utah death certificate indicating prostate cancer as a contributing cause of death.
A set of markers with no linkage disequilibrium was selected for linkage analysis.
We took the intersection of SNP markers from five Illumina genotyping platforms used (550K, 610K, 1M,Omni_express (720k), and Omni_1M), resulting in selection of 301,646 markers.
We began with the first marker on each chromosome and then skipped markers until one satisfied all criteria (min 0.
1 cM distance, heterozygosity 0.
35, R-squared < 0.
16 -using HapMap's LD files based on CEPH).
This resulted in selection of a set of 25,436 SNP LD-free genome wide markers for linkage.
We have performed genome-wide linkage analysis for 21 of the genotyped high-risk lethal prostate cancer pedigrees with the 25,436 selected SNP markers.
Genome wide hetLODs showed one significant linkage peak for the recessive model on chromosome 14 (LOD = 4.
20).
The pedigree with the highest LOD in this region has a +2.
69; we are attempting to expand sampling for other pedigrees with linkage evidence in this region.
A single pedigree with 16 prostate cancer cases, at least 4 of whom have already died from prostate cancer and were sampled, provided a LOD score = +3.
56 on chromosome arm 11p15.
An 11p15 haplotype inherited in common from the founder to 6 generations of descendants is shared in at least 9 of the prostate cancer cases, 3 of whom died from prostate cancer.
The 1-LOD drop defined support interval for the pedigree linked to chromosome 11 occurs at approximately 34-46 cM and contains 13 currently documented genomic features, several of which may be reasonable candidates for lethal prostate cancer including the gene PRMT3 (arginine methyltransferase 3), DAL-1, NELL1, FANCF (Fanconi anemia, complementation group F), and GAS2 (growth arrest-specific 2).
Sequencing of multiple haplotype sharing cases in the pedigree is underway.
Citation Format: Lisa A.
Cannon-Albright, Craig C.
Teerlink, Neeraj Agarwal.
Identification of significant linkage evidence for lethal prostate cancer on chromosome arm 11p15.
[abstract].
In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC.
Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1341.
doi:10.
1158/1538-7445.
AM2013-1341.
Related Results
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract
Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeri...
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract
The human olfactomedin 4 gene (OLFM4) encodes an olfactomedin-related glycoprotein, which our group first cloned and characterized in myeloid cells and mapp...
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract
BACKGROUND: Multiple steps and factors are involved in prostate carcinogenesis and tumor progression. The early studies have found that tumor-associated mac...
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
ImportanceAdvocates for removing the cancer label from grade group 1 (GG1) prostate cancer detected on biopsy primarily base their argument on the observation that when only GG1 is...
Description of the international consortium for prostate cancer genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13
Description of the international consortium for prostate cancer genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13
AbstractThe International Consortium for Prostate Cancer Genetics (ICPCG) is an international collaborative effort to pool pedigrees with hereditary prostate cancer (PC) in order t...
Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study
Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study
Background: Early prostate cancer antigen (EPCA), a nuclear matrix protein, has recently been recommended as a hopeful biomarker for early prostate carcinogenesis. Objectives: To e...
Data from Dietary Fructose Promotes Prostate Cancer Growth
Data from Dietary Fructose Promotes Prostate Cancer Growth
<div>Abstract<p>Clinical localization of primary tumors and sites of metastasis by PET is based on the enhanced cellular uptake of 2-deoxy-2-[<sup>18</sup>F...
PROSTATE CANCER EPIDEMIOLOGY IN THE EAST KAZAKHSTAN REGION, 2010-2019
PROSTATE CANCER EPIDEMIOLOGY IN THE EAST KAZAKHSTAN REGION, 2010-2019
Relevance: From 2010 to 2019, prostate cancer morbidity increased, and prostate cancer mortality decreased in Kazakhstan. The peak incidence was observed in patients aged 70 years ...

